Denosumab (Prolia®) for the treatment of osteoporosis

Moshi M, Nicolopoulos K, Stringer D, Gaget V, Ma N, Vreugdenburg T
Record ID 32018001645
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Switzerland
MeSH Terms
  • Osteoporosis
  • Osteoporosis, Postmenopausal
  • Denosumab
  • Bone Density Conservation Agents
  • Diphosphonates
  • Selective Estrogen Receptor Modulators
  • osteoporosis
  • denosumab
  • bisphosphonates
  • selective oestrogen receptor modulators
  • PROMs
  • efficacy
  • effectiveness
  • safety
  • costs
  • economics
  • cost-effectiveness
  • budget impact
  • legal
  • social
  • ethical
  • organisational
Organisation Name: Swiss Federal Office of Public Health (FOPH)
Contact Address: Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name: Stephanie Vollenweider
Contact Email:
Copyright: Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.